Income StatementBalance SheetCash FlowBusiness Segments
Eli Lilly logo

Eli Lilly Income Statement

Revenue, expenses, and profitability over time

Eli Lilly generated $65.2B in trailing twelve-month revenue, up 0.4% year-over-year. Net income was $20.6B with a 31.67% net margin. Diluted EPS is $22.95, which grew 1.0% year-over-year. Based on the Q4 2025 filing.

Total Revenue (TTM)$65.2BNet Income (TTM)$20.6BEps Diluted (TTM)$22.95
Latest FilingQ4 2025
Report Date2026-02-12
Market Cap$784.58B
P/E Ratio38.01
ROE101.36%

Earnings Per Share

MetricQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Basic earnings per share$1.08$4.90$3.07$6.30$6.22$7.41
Diluted earnings per share$1.07$4.88$3.06$6.29$6.21$7.39
Weighted-average shares, basic901M—898.7M897.9M896.9M—
Weighted-average shares, diluted905M—900.6M899.8M898.8M—

Income Before Tax

MetricQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Income before income taxes$1.6B$5.0B$3.5B$6.8B$7.2B$8.3B

Tax

MetricQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Income tax expense$618.1M$628.9M$696.8M$1.1B$1.6B$1.6B

Operating Expenses

MetricQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Acquired in-process research and development$2.8B$189.2M$1.6B$153.8M$655.7M$528.8M
Cost of sales, operating expenses, and other-net$9.9B$8.5B$9.3B$8.8B$10.4B$11.0B
Impairment and restructuring$81.6M$344.0M$35.0M$0.0$364.9M$84.1M
Research and development$2.7B$3.0B$2.7B$3.3B$3.5B$3.8B
Selling, general and administrative$2.1B$2.4B$2.5B$2.8B$2.7B$3.1B

Net Income

MetricQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Net income$970.3M$4.4B$2.8B$5.7B$5.6B$6.6B

Other Income & Expense

MetricQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Other income (expense), net$62.0M-$110.1M-$239.0M-$90.6M-$133.1M-$108.3M

Cost of Revenue

MetricQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Total cost of revenue$2.2B$2.4B$2.2B$2.4B$3.0B$3.4B

Revenue

MetricQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Total revenue$11.4B$13.5B$12.7B$15.6B$17.6B$19.3B

Cookie Preferences

We use cookies for analytics. See our Privacy and Cookie Policy.